ArticleJournal of Cancer2026
Mitochondrial Parameters influence Chemosensitivity in Gastric Cancer Cells.
Article in Journal of Cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mitochondria play crucial roles in the survival of malignant cells in gastric and other types of cancers, and many cancer treatments act at least in part via mitochondrial effects. Although several measurable mitochondrial parameters have been associated with sensitivity of certain cancer cells to treatments, it remains unclear how these parameters differ among cancer cells according to differentiation level and histological type. It also remains unclear whether and how the effects of chemotherapy on mitochondrial parameters might be associated with sensitivity to treatment. In this study, we compared mitochondrial parameters in a panel of gastric cancer cell lines with different characteristics, including AGS (moderately differentiated), SNU-1 (poorly differentiated), KATO III (signet ring cell carcinoma; SRCC), and NUGC-4 (SRCC). We examined differences in basal mitochondrial parameters between the cell lines and the impacts of chemotherapy on each parameter. Our results showed that each cell line showed a different response pattern to cisplatin and 5-fluorouracil. For example, cisplatin was much more effective than 5-fluorouracil at killing SNU-1 gastric cancer cells, while KATO III cells exhibited minimal responses to both chemotherapies. These patterns of cytotoxicity were closely aligned with mitochondrial membrane potential. The different gastric cancer cell lines also displayed differences in basal mitochondrial parameters, but the basal measurements did not directly correlate with sensitivity to chemotherapy. Nevertheless, sensitivity was associated with an integrated profile of basal levels and effects of chemotherapy on mitochondrial parameters. Thus, our study highlights the association between mitochondrial parameters and chemosensitivity among gastric cancer cells with diverse characteristics. These findings may guide the development of more precise treatment strategies and targeted therapies for distinct types of gastric cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.